SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 18, 2019
SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
501 Canal Blvd., Richmond, California 94804
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former name or former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 18, 2019, Steven Mento, Ph.D., notified Sangamo Therapeutics, Inc. (the Company) of his decision not to stand for re-election to the Board of Directors of the Company (the Board) at the 2019 annual meeting of stockholders of the Company (the Annual Meeting). As a result, Dr. Mentos service as a member of the Board will expire at the Annual Meeting. Dr. Mento indicated that his decision not to stand for re-election was not a result of any disagreement with the Company on any matter relating to the Companys operations, policies or practices.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: March 21, 2019
|SANGAMO THERAPEUTICS, INC.|
|Alexander D. Macrae, M.B., Ch.B., Ph.D.|
|President, Chief Executive Officer|